A clinical briefing on Blisovi 21 Fe 1.5/30 28 Day Pack availability in 2026. Supply data, prescribing strategies, alternatives, and tools for providers.
Patients are increasingly presenting to your office with the same complaint: they can't fill their Blisovi 21 Fe 1.5/30 28 Day Pack prescription. As a prescriber, you need accurate, up-to-date information to advise patients and adjust your prescribing workflow when necessary.
This briefing covers the current supply picture, prescribing implications, therapeutically equivalent alternatives, and tools that can help both you and your patients navigate ongoing availability challenges.
Blisovi Fe 1.5/30 (norethindrone acetate 1.5 mg/ethinyl estradiol 30 mcg with ferrous fumarate) is manufactured by Lupin Pharmaceuticals and has been marketed since receiving FDA approval in 2018.
Key timeline points:
The intermittent availability of Blisovi Fe 1.5/30 creates several clinical considerations:
Gaps in oral contraceptive supply directly impact patient adherence and increase unintended pregnancy risk. Patients who miss even 2–3 days of active pills may lose ovulatory suppression, particularly in the first week of a new pack. Counsel patients to use backup contraception if they experience any gap in pill access.
All of the following are FDA-rated as therapeutically equivalent (AB-rated) to Loestrin Fe 1.5/30 and contain identical active ingredients:
In most states, pharmacists can substitute between AB-rated generics without prescriber authorization unless "dispense as written" (DAW) is indicated. Consider writing prescriptions with generic names (norethindrone acetate/ethinyl estradiol 1.5 mg/0.03 mg with ferrous fumarate) to give pharmacists maximum flexibility.
Under the ACA preventive care mandate, most insurance plans must cover at least one formulation within each contraceptive category at $0 cost-sharing. However, individual plan formularies may prefer specific generics. If a patient's plan does not cover Blisovi but covers Junel, the substitution is clinically seamless.
Based on current data:
Medfinder for Providers offers real-time pharmacy availability data, enabling you to direct patients to specific pharmacies that currently have Blisovi Fe 1.5/30 or its equivalents in stock.
For insured patients, most plans cover generic oral contraceptives at $0 copay under the ACA contraceptive mandate. For uninsured patients:
Several resources can streamline your workflow when patients report difficulty finding their medication:
The underlying factors driving intermittent availability — manufacturing consolidation, global supply chain dependencies, and demand-shifting between generic brands — are structural issues unlikely to resolve quickly. Providers should expect periodic patient inquiries about availability for the foreseeable future.
Proactive strategies include:
For a patient-facing version of this information, see our Blisovi Fe 1.5/30 shortage update for patients.
Blisovi 21 Fe 1.5/30 28 Day Pack remains a safe and effective contraceptive option with strong therapeutic equivalents available. The supply situation in 2026 is manageable with proactive prescribing, patient education, and the right tools. Helping patients understand they have identical alternatives — and connecting them with pharmacies that have stock — can prevent gaps in contraceptive coverage and reduce the clinical burden on your practice.
Visit Medfinder for Providers to access real-time availability data for Blisovi Fe 1.5/30 and other medications.
You focus on staying healthy. We'll handle the rest.
Try Medfinder Concierge FreeMedfinder's mission is to ensure every patient gets access to the medications they need. We believe this begins with trustworthy information. Our core values guide everything we do, including the standards that shape the accuracy, transparency, and quality of our content. We’re committed to delivering information that’s evidence-based, regularly updated, and easy to understand. For more details on our editorial process, see here.
%2C%20Color%3DOriginal.png)
